Managing Safety Signals in Large Endpoint Trials

Publisher： Bentham Science Publishers

E-ISSN： 2212-3911|3|2|86-90

ISSN： 1574-8863

Source： Current Drug Safety, Vol.3, Iss.2, 2008-05, pp. : 86-90

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Is Doubling of Serum Creatinine a Valid Clinical ‘Hard’ Endpoint in Clinical Nephrology Trials?

By  

Nephron Clin Pract, Vol. 119, Iss. 3, 2011-08 ,pp. : c195-c199

Karger

Access to resources Recommend Favorite

Lessons for the monitoring of safety in clinical trials

By  

EUROPEAN JOURNAL OF HEART FAILURE, Vol. 20, Iss. 1, 2018-01 ,pp. : 148-148

John Wiley & Sons Inc

Access to resources Recommend Favorite

Overall Survival Endpoint in Oncology Clinical Trials: Addressing the Effect of Crossover - The Case of Pazopanib in Advanced Renal Cell Carcinoma

By  

Oncology, Vol. 90, Iss. 3, 2016-02 ,pp. : 119-126

Karger

Access to resources Recommend Favorite

Defining and Managing Expectations for Early Immunotherapy Cancer Trials

By  

Reviews on Recent Clinical Trials, Vol. 10, Iss. 1, 2015-05 ,pp. : 47-60

Bentham Science Publishers

Access to resources Recommend Favorite

Recent clinical trials in diabetes – implications for managing older patients

By  

Reviews in Clinical Gerontology, Vol. 19, Iss. 1, 2009-02 ,pp. : 25-33

Cambridge University Press

Access to resources Recommend Favorite